Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011626 | 0.84 | ADORA2A (0.42) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL940801 | 0.84 | ADORA2A (0.42) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL6489832 | 0.83 | ADORA3 (0.49) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL2013404 | 0.83 | MAPT (0.38) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL2008817 | 0.79 | ADORA2A (0.42) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL939938 | 0.71 | KMT2A (0.37) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL27683894 | 0.71 | KDM4E (0.40) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL6480105 | 0.70 | ADORA3 (0.46) | KDM4EHPGDMAPTHSD17B10TSHR | |
| SCHEMBL6489955 | 0.70 | ADORA3 (0.44) | ADORA2AADORA1KDM4EHPGDMAPT | |
| SCHEMBL940002 | 0.69 | ADORA1 (0.42) | ADORA2AADORA1KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964731-B2 | Isotopically marked quinoline derivatives as adenosin A3 receptor ligands | SANOFI-AVENTIS (FR) | 2011-06-21 | — | — | US | disclosed |
| EP-1814857-B1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-09-01 | — | — | EP | disclosed |
| US-20080027225-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1814857-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051341-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027225-A1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | ACKR3, ADORA3, CIAPIN1 | ADORA2A 8/4885ADORA1 28/4885KDM4E 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.